Microbiome Therapeutics research
Microbiome Therapeutics research

Microbiome Therapeutics Comprehensive Study by Type (FMT, Microbiome drugs), Indication (Type 2 diabetes, Obesity, C. difficile Infection, Primary Hyperoxyurea), Technology (Sequencing, Genomic Technologies {Polymerase Chain Reaction (PCR), Fluorescence In Situ Hybridization (FISH), and DNA Microarrays}, Proteomics, Metabolomics) Players and Region - Global Market Outlook to 2025

Microbiome Therapeutics Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025  

Nov 2020 Edition 206 Pages 169 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Microbiome Therapeutics Market Scope
Microbiome therapy aims to establish a healthy gut microbiome to restore gut function and prevent dysregulation. Microbiome therapies are currently in development to prevent recurrent C. difficile infections, which are primarily contracted in hospitals, leading to diarrhea, dehydration, fever, and weight loss. Advancement in microbiome technologies would assist in determining the probable solutions for serious diseases; these technologies would thus improve healthcare outcomes. Companies are undertaking strategic initiatives such as new product development and venture capital investments for catering to greater opportunities in both developed and developing countries.

The Microbiome Therapeutics market study is segmented by Type (FMT and Microbiome drugs) and major geographies with country level break-up.

The players highly focusing on business growth strategies such including new product launch, merger & acquisitions, Licensing partnerships, and others to become more competitive in the market. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Microbiome Therapeutics market throughout the predicted period.

Armata Pharmaceuticals (United States), Enterome Bioscience (France), Immuron (Australia), OpenBiome (United States), Osel (United States), LNC Therapeutics (France), ViThera Pharmaceuticals (United States), Ferring Pharmaceuticals (Switzerland), Second Genome (United States) and Vedanta Biosciences (United States) are some of the key players that are part of study coverage.

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Microbiome Therapeutics market by Type, Application and Region.

On the basis of geography, the market of Microbiome Therapeutics has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Market Leaders and their expansionary development strategies
In Mar 2019, the Seres Company has collaborated with AstraZeneca, which will help to get a better microbiome in augmenting the efficacy of cancer immunotherapy. Hence, this microbiome will affect the growth of the market in the future.
In May 2020, Rebiotix and Ferring Pharmaceuticals announced positive preliminary findings from their ongoing pivotal Phase 3 trial of the investigational microbiome-based treatment, RBX2660. These preliminary positive efficacy findings mark an important milestone, advancing RBX2660 in its clinical development program with a goal of bringing a US FDA approved therapy to patients.


Market Trend
  • Rising Clinical Trials in the Microbiome Therapy

Market Drivers
  • Increasing Prevalence of Diseases due to Dysbiosis of Microbiota in the Gut
  • High Amount of Funding for Biological Drug Development Studies

Opportunities
  • Increasing Collaboration between Pharmaceutical Companies for the Development of Novel Drugs
  • Growing Demand from Emerging Market such as China, India, among others

Restraints
  • Lack of Clear Regulatory Pathways
  • Delays in Launch of Microbiome Therapeutics

Challenges
  • Lack of Expertise as well as Detailed Research


Key Target Audience
Venture Capitalists and Private Equity Firms, New Entrants/Investors, Analyst and Strategic Business Planners, Microbiome Therapeutics Devices and Drugs Manufacturers, Suppliers, and Distributors, Key Raw Material Manufacturers, Government Regulatory and Research Organizations and End-Use Industries

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • FMT
  • Microbiome drugs
By Indication
  • Type 2 diabetes
  • Obesity
  • C. difficile Infection
  • Primary Hyperoxyurea

By Technology
  • Sequencing
  • Genomic Technologies {Polymerase Chain Reaction (PCR), Fluorescence In Situ Hybridization (FISH), and DNA Microarrays}
  • Proteomics
  • Metabolomics

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Prevalence of Diseases due to Dysbiosis of Microbiota in the Gut
      • 3.2.2. High Amount of Funding for Biological Drug Development Studies
    • 3.3. Market Challenges
      • 3.3.1. Lack of Expertise as well as Detailed Research
    • 3.4. Market Trends
      • 3.4.1. Rising Clinical Trials in the Microbiome Therapy
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Microbiome Therapeutics, by Type, Indication, Technology and Region (value) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Microbiome Therapeutics (Value)
      • 5.2.1. Global Microbiome Therapeutics by: Type (Value)
        • 5.2.1.1. FMT
        • 5.2.1.2. Microbiome drugs
      • 5.2.2. Global Microbiome Therapeutics by: Indication (Value)
        • 5.2.2.1. Type 2 diabetes
        • 5.2.2.2. Obesity
        • 5.2.2.3. C. difficile Infection
        • 5.2.2.4. Primary Hyperoxyurea
      • 5.2.3. Global Microbiome Therapeutics by: Technology (Value)
        • 5.2.3.1. Sequencing
        • 5.2.3.2. Genomic Technologies {Polymerase Chain Reaction (PCR), Fluorescence In Situ Hybridization (FISH), and DNA Microarrays}
        • 5.2.3.3. Proteomics
        • 5.2.3.4. Metabolomics
      • 5.2.4. Global Microbiome Therapeutics Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Microbiome Therapeutics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Armata Pharmaceuticals (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Enterome Bioscience (France)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Immuron (Australia)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. OpenBiome (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Osel (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. LNC Therapeutics (France)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. ViThera Pharmaceuticals (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Ferring Pharmaceuticals (Switzerland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Second Genome (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Vedanta Biosciences (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Microbiome Therapeutics Sale, by Type, Indication, Technology and Region (value) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global Microbiome Therapeutics (Value)
      • 7.2.1. Global Microbiome Therapeutics by: Type (Value)
        • 7.2.1.1. FMT
        • 7.2.1.2. Microbiome drugs
      • 7.2.2. Global Microbiome Therapeutics by: Indication (Value)
        • 7.2.2.1. Type 2 diabetes
        • 7.2.2.2. Obesity
        • 7.2.2.3. C. difficile Infection
        • 7.2.2.4. Primary Hyperoxyurea
      • 7.2.3. Global Microbiome Therapeutics by: Technology (Value)
        • 7.2.3.1. Sequencing
        • 7.2.3.2. Genomic Technologies {Polymerase Chain Reaction (PCR), Fluorescence In Situ Hybridization (FISH), and DNA Microarrays}
        • 7.2.3.3. Proteomics
        • 7.2.3.4. Metabolomics
      • 7.2.4. Global Microbiome Therapeutics Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Microbiome Therapeutics: by Type(USD Million)
  • Table 2. Microbiome Therapeutics FMT , by Region USD Million (2014-2019)
  • Table 3. Microbiome Therapeutics Microbiome drugs , by Region USD Million (2014-2019)
  • Table 4. Microbiome Therapeutics: by Indication(USD Million)
  • Table 5. Microbiome Therapeutics Type 2 diabetes , by Region USD Million (2014-2019)
  • Table 6. Microbiome Therapeutics Obesity , by Region USD Million (2014-2019)
  • Table 7. Microbiome Therapeutics C. difficile Infection , by Region USD Million (2014-2019)
  • Table 8. Microbiome Therapeutics Primary Hyperoxyurea , by Region USD Million (2014-2019)
  • Table 9. Microbiome Therapeutics: by Technology(USD Million)
  • Table 10. Microbiome Therapeutics Sequencing , by Region USD Million (2014-2019)
  • Table 11. Microbiome Therapeutics Genomic Technologies {Polymerase Chain Reaction (PCR), Fluorescence In Situ Hybridization (FISH), and DNA Microarrays} , by Region USD Million (2014-2019)
  • Table 12. Microbiome Therapeutics Proteomics , by Region USD Million (2014-2019)
  • Table 13. Microbiome Therapeutics Metabolomics , by Region USD Million (2014-2019)
  • Table 14. South America Microbiome Therapeutics, by Country USD Million (2014-2019)
  • Table 15. South America Microbiome Therapeutics, by Type USD Million (2014-2019)
  • Table 16. South America Microbiome Therapeutics, by Indication USD Million (2014-2019)
  • Table 17. South America Microbiome Therapeutics, by Technology USD Million (2014-2019)
  • Table 18. Brazil Microbiome Therapeutics, by Type USD Million (2014-2019)
  • Table 19. Brazil Microbiome Therapeutics, by Indication USD Million (2014-2019)
  • Table 20. Brazil Microbiome Therapeutics, by Technology USD Million (2014-2019)
  • Table 21. Argentina Microbiome Therapeutics, by Type USD Million (2014-2019)
  • Table 22. Argentina Microbiome Therapeutics, by Indication USD Million (2014-2019)
  • Table 23. Argentina Microbiome Therapeutics, by Technology USD Million (2014-2019)
  • Table 24. Rest of South America Microbiome Therapeutics, by Type USD Million (2014-2019)
  • Table 25. Rest of South America Microbiome Therapeutics, by Indication USD Million (2014-2019)
  • Table 26. Rest of South America Microbiome Therapeutics, by Technology USD Million (2014-2019)
  • Table 27. Asia Pacific Microbiome Therapeutics, by Country USD Million (2014-2019)
  • Table 28. Asia Pacific Microbiome Therapeutics, by Type USD Million (2014-2019)
  • Table 29. Asia Pacific Microbiome Therapeutics, by Indication USD Million (2014-2019)
  • Table 30. Asia Pacific Microbiome Therapeutics, by Technology USD Million (2014-2019)
  • Table 31. China Microbiome Therapeutics, by Type USD Million (2014-2019)
  • Table 32. China Microbiome Therapeutics, by Indication USD Million (2014-2019)
  • Table 33. China Microbiome Therapeutics, by Technology USD Million (2014-2019)
  • Table 34. Japan Microbiome Therapeutics, by Type USD Million (2014-2019)
  • Table 35. Japan Microbiome Therapeutics, by Indication USD Million (2014-2019)
  • Table 36. Japan Microbiome Therapeutics, by Technology USD Million (2014-2019)
  • Table 37. India Microbiome Therapeutics, by Type USD Million (2014-2019)
  • Table 38. India Microbiome Therapeutics, by Indication USD Million (2014-2019)
  • Table 39. India Microbiome Therapeutics, by Technology USD Million (2014-2019)
  • Table 40. South Korea Microbiome Therapeutics, by Type USD Million (2014-2019)
  • Table 41. South Korea Microbiome Therapeutics, by Indication USD Million (2014-2019)
  • Table 42. South Korea Microbiome Therapeutics, by Technology USD Million (2014-2019)
  • Table 43. Taiwan Microbiome Therapeutics, by Type USD Million (2014-2019)
  • Table 44. Taiwan Microbiome Therapeutics, by Indication USD Million (2014-2019)
  • Table 45. Taiwan Microbiome Therapeutics, by Technology USD Million (2014-2019)
  • Table 46. Australia Microbiome Therapeutics, by Type USD Million (2014-2019)
  • Table 47. Australia Microbiome Therapeutics, by Indication USD Million (2014-2019)
  • Table 48. Australia Microbiome Therapeutics, by Technology USD Million (2014-2019)
  • Table 49. Rest of Asia-Pacific Microbiome Therapeutics, by Type USD Million (2014-2019)
  • Table 50. Rest of Asia-Pacific Microbiome Therapeutics, by Indication USD Million (2014-2019)
  • Table 51. Rest of Asia-Pacific Microbiome Therapeutics, by Technology USD Million (2014-2019)
  • Table 52. Europe Microbiome Therapeutics, by Country USD Million (2014-2019)
  • Table 53. Europe Microbiome Therapeutics, by Type USD Million (2014-2019)
  • Table 54. Europe Microbiome Therapeutics, by Indication USD Million (2014-2019)
  • Table 55. Europe Microbiome Therapeutics, by Technology USD Million (2014-2019)
  • Table 56. Germany Microbiome Therapeutics, by Type USD Million (2014-2019)
  • Table 57. Germany Microbiome Therapeutics, by Indication USD Million (2014-2019)
  • Table 58. Germany Microbiome Therapeutics, by Technology USD Million (2014-2019)
  • Table 59. France Microbiome Therapeutics, by Type USD Million (2014-2019)
  • Table 60. France Microbiome Therapeutics, by Indication USD Million (2014-2019)
  • Table 61. France Microbiome Therapeutics, by Technology USD Million (2014-2019)
  • Table 62. Italy Microbiome Therapeutics, by Type USD Million (2014-2019)
  • Table 63. Italy Microbiome Therapeutics, by Indication USD Million (2014-2019)
  • Table 64. Italy Microbiome Therapeutics, by Technology USD Million (2014-2019)
  • Table 65. United Kingdom Microbiome Therapeutics, by Type USD Million (2014-2019)
  • Table 66. United Kingdom Microbiome Therapeutics, by Indication USD Million (2014-2019)
  • Table 67. United Kingdom Microbiome Therapeutics, by Technology USD Million (2014-2019)
  • Table 68. Netherlands Microbiome Therapeutics, by Type USD Million (2014-2019)
  • Table 69. Netherlands Microbiome Therapeutics, by Indication USD Million (2014-2019)
  • Table 70. Netherlands Microbiome Therapeutics, by Technology USD Million (2014-2019)
  • Table 71. Rest of Europe Microbiome Therapeutics, by Type USD Million (2014-2019)
  • Table 72. Rest of Europe Microbiome Therapeutics, by Indication USD Million (2014-2019)
  • Table 73. Rest of Europe Microbiome Therapeutics, by Technology USD Million (2014-2019)
  • Table 74. MEA Microbiome Therapeutics, by Country USD Million (2014-2019)
  • Table 75. MEA Microbiome Therapeutics, by Type USD Million (2014-2019)
  • Table 76. MEA Microbiome Therapeutics, by Indication USD Million (2014-2019)
  • Table 77. MEA Microbiome Therapeutics, by Technology USD Million (2014-2019)
  • Table 78. Middle East Microbiome Therapeutics, by Type USD Million (2014-2019)
  • Table 79. Middle East Microbiome Therapeutics, by Indication USD Million (2014-2019)
  • Table 80. Middle East Microbiome Therapeutics, by Technology USD Million (2014-2019)
  • Table 81. Africa Microbiome Therapeutics, by Type USD Million (2014-2019)
  • Table 82. Africa Microbiome Therapeutics, by Indication USD Million (2014-2019)
  • Table 83. Africa Microbiome Therapeutics, by Technology USD Million (2014-2019)
  • Table 84. North America Microbiome Therapeutics, by Country USD Million (2014-2019)
  • Table 85. North America Microbiome Therapeutics, by Type USD Million (2014-2019)
  • Table 86. North America Microbiome Therapeutics, by Indication USD Million (2014-2019)
  • Table 87. North America Microbiome Therapeutics, by Technology USD Million (2014-2019)
  • Table 88. United States Microbiome Therapeutics, by Type USD Million (2014-2019)
  • Table 89. United States Microbiome Therapeutics, by Indication USD Million (2014-2019)
  • Table 90. United States Microbiome Therapeutics, by Technology USD Million (2014-2019)
  • Table 91. Canada Microbiome Therapeutics, by Type USD Million (2014-2019)
  • Table 92. Canada Microbiome Therapeutics, by Indication USD Million (2014-2019)
  • Table 93. Canada Microbiome Therapeutics, by Technology USD Million (2014-2019)
  • Table 94. Mexico Microbiome Therapeutics, by Type USD Million (2014-2019)
  • Table 95. Mexico Microbiome Therapeutics, by Indication USD Million (2014-2019)
  • Table 96. Mexico Microbiome Therapeutics, by Technology USD Million (2014-2019)
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Microbiome Therapeutics: by Type(USD Million)
  • Table 108. Microbiome Therapeutics FMT , by Region USD Million (2020-2025)
  • Table 109. Microbiome Therapeutics Microbiome drugs , by Region USD Million (2020-2025)
  • Table 110. Microbiome Therapeutics: by Indication(USD Million)
  • Table 111. Microbiome Therapeutics Type 2 diabetes , by Region USD Million (2020-2025)
  • Table 112. Microbiome Therapeutics Obesity , by Region USD Million (2020-2025)
  • Table 113. Microbiome Therapeutics C. difficile Infection , by Region USD Million (2020-2025)
  • Table 114. Microbiome Therapeutics Primary Hyperoxyurea , by Region USD Million (2020-2025)
  • Table 115. Microbiome Therapeutics: by Technology(USD Million)
  • Table 116. Microbiome Therapeutics Sequencing , by Region USD Million (2020-2025)
  • Table 117. Microbiome Therapeutics Genomic Technologies {Polymerase Chain Reaction (PCR), Fluorescence In Situ Hybridization (FISH), and DNA Microarrays} , by Region USD Million (2020-2025)
  • Table 118. Microbiome Therapeutics Proteomics , by Region USD Million (2020-2025)
  • Table 119. Microbiome Therapeutics Metabolomics , by Region USD Million (2020-2025)
  • Table 120. South America Microbiome Therapeutics, by Country USD Million (2020-2025)
  • Table 121. South America Microbiome Therapeutics, by Type USD Million (2020-2025)
  • Table 122. South America Microbiome Therapeutics, by Indication USD Million (2020-2025)
  • Table 123. South America Microbiome Therapeutics, by Technology USD Million (2020-2025)
  • Table 124. Brazil Microbiome Therapeutics, by Type USD Million (2020-2025)
  • Table 125. Brazil Microbiome Therapeutics, by Indication USD Million (2020-2025)
  • Table 126. Brazil Microbiome Therapeutics, by Technology USD Million (2020-2025)
  • Table 127. Argentina Microbiome Therapeutics, by Type USD Million (2020-2025)
  • Table 128. Argentina Microbiome Therapeutics, by Indication USD Million (2020-2025)
  • Table 129. Argentina Microbiome Therapeutics, by Technology USD Million (2020-2025)
  • Table 130. Rest of South America Microbiome Therapeutics, by Type USD Million (2020-2025)
  • Table 131. Rest of South America Microbiome Therapeutics, by Indication USD Million (2020-2025)
  • Table 132. Rest of South America Microbiome Therapeutics, by Technology USD Million (2020-2025)
  • Table 133. Asia Pacific Microbiome Therapeutics, by Country USD Million (2020-2025)
  • Table 134. Asia Pacific Microbiome Therapeutics, by Type USD Million (2020-2025)
  • Table 135. Asia Pacific Microbiome Therapeutics, by Indication USD Million (2020-2025)
  • Table 136. Asia Pacific Microbiome Therapeutics, by Technology USD Million (2020-2025)
  • Table 137. China Microbiome Therapeutics, by Type USD Million (2020-2025)
  • Table 138. China Microbiome Therapeutics, by Indication USD Million (2020-2025)
  • Table 139. China Microbiome Therapeutics, by Technology USD Million (2020-2025)
  • Table 140. Japan Microbiome Therapeutics, by Type USD Million (2020-2025)
  • Table 141. Japan Microbiome Therapeutics, by Indication USD Million (2020-2025)
  • Table 142. Japan Microbiome Therapeutics, by Technology USD Million (2020-2025)
  • Table 143. India Microbiome Therapeutics, by Type USD Million (2020-2025)
  • Table 144. India Microbiome Therapeutics, by Indication USD Million (2020-2025)
  • Table 145. India Microbiome Therapeutics, by Technology USD Million (2020-2025)
  • Table 146. South Korea Microbiome Therapeutics, by Type USD Million (2020-2025)
  • Table 147. South Korea Microbiome Therapeutics, by Indication USD Million (2020-2025)
  • Table 148. South Korea Microbiome Therapeutics, by Technology USD Million (2020-2025)
  • Table 149. Taiwan Microbiome Therapeutics, by Type USD Million (2020-2025)
  • Table 150. Taiwan Microbiome Therapeutics, by Indication USD Million (2020-2025)
  • Table 151. Taiwan Microbiome Therapeutics, by Technology USD Million (2020-2025)
  • Table 152. Australia Microbiome Therapeutics, by Type USD Million (2020-2025)
  • Table 153. Australia Microbiome Therapeutics, by Indication USD Million (2020-2025)
  • Table 154. Australia Microbiome Therapeutics, by Technology USD Million (2020-2025)
  • Table 155. Rest of Asia-Pacific Microbiome Therapeutics, by Type USD Million (2020-2025)
  • Table 156. Rest of Asia-Pacific Microbiome Therapeutics, by Indication USD Million (2020-2025)
  • Table 157. Rest of Asia-Pacific Microbiome Therapeutics, by Technology USD Million (2020-2025)
  • Table 158. Europe Microbiome Therapeutics, by Country USD Million (2020-2025)
  • Table 159. Europe Microbiome Therapeutics, by Type USD Million (2020-2025)
  • Table 160. Europe Microbiome Therapeutics, by Indication USD Million (2020-2025)
  • Table 161. Europe Microbiome Therapeutics, by Technology USD Million (2020-2025)
  • Table 162. Germany Microbiome Therapeutics, by Type USD Million (2020-2025)
  • Table 163. Germany Microbiome Therapeutics, by Indication USD Million (2020-2025)
  • Table 164. Germany Microbiome Therapeutics, by Technology USD Million (2020-2025)
  • Table 165. France Microbiome Therapeutics, by Type USD Million (2020-2025)
  • Table 166. France Microbiome Therapeutics, by Indication USD Million (2020-2025)
  • Table 167. France Microbiome Therapeutics, by Technology USD Million (2020-2025)
  • Table 168. Italy Microbiome Therapeutics, by Type USD Million (2020-2025)
  • Table 169. Italy Microbiome Therapeutics, by Indication USD Million (2020-2025)
  • Table 170. Italy Microbiome Therapeutics, by Technology USD Million (2020-2025)
  • Table 171. United Kingdom Microbiome Therapeutics, by Type USD Million (2020-2025)
  • Table 172. United Kingdom Microbiome Therapeutics, by Indication USD Million (2020-2025)
  • Table 173. United Kingdom Microbiome Therapeutics, by Technology USD Million (2020-2025)
  • Table 174. Netherlands Microbiome Therapeutics, by Type USD Million (2020-2025)
  • Table 175. Netherlands Microbiome Therapeutics, by Indication USD Million (2020-2025)
  • Table 176. Netherlands Microbiome Therapeutics, by Technology USD Million (2020-2025)
  • Table 177. Rest of Europe Microbiome Therapeutics, by Type USD Million (2020-2025)
  • Table 178. Rest of Europe Microbiome Therapeutics, by Indication USD Million (2020-2025)
  • Table 179. Rest of Europe Microbiome Therapeutics, by Technology USD Million (2020-2025)
  • Table 180. MEA Microbiome Therapeutics, by Country USD Million (2020-2025)
  • Table 181. MEA Microbiome Therapeutics, by Type USD Million (2020-2025)
  • Table 182. MEA Microbiome Therapeutics, by Indication USD Million (2020-2025)
  • Table 183. MEA Microbiome Therapeutics, by Technology USD Million (2020-2025)
  • Table 184. Middle East Microbiome Therapeutics, by Type USD Million (2020-2025)
  • Table 185. Middle East Microbiome Therapeutics, by Indication USD Million (2020-2025)
  • Table 186. Middle East Microbiome Therapeutics, by Technology USD Million (2020-2025)
  • Table 187. Africa Microbiome Therapeutics, by Type USD Million (2020-2025)
  • Table 188. Africa Microbiome Therapeutics, by Indication USD Million (2020-2025)
  • Table 189. Africa Microbiome Therapeutics, by Technology USD Million (2020-2025)
  • Table 190. North America Microbiome Therapeutics, by Country USD Million (2020-2025)
  • Table 191. North America Microbiome Therapeutics, by Type USD Million (2020-2025)
  • Table 192. North America Microbiome Therapeutics, by Indication USD Million (2020-2025)
  • Table 193. North America Microbiome Therapeutics, by Technology USD Million (2020-2025)
  • Table 194. United States Microbiome Therapeutics, by Type USD Million (2020-2025)
  • Table 195. United States Microbiome Therapeutics, by Indication USD Million (2020-2025)
  • Table 196. United States Microbiome Therapeutics, by Technology USD Million (2020-2025)
  • Table 197. Canada Microbiome Therapeutics, by Type USD Million (2020-2025)
  • Table 198. Canada Microbiome Therapeutics, by Indication USD Million (2020-2025)
  • Table 199. Canada Microbiome Therapeutics, by Technology USD Million (2020-2025)
  • Table 200. Mexico Microbiome Therapeutics, by Type USD Million (2020-2025)
  • Table 201. Mexico Microbiome Therapeutics, by Indication USD Million (2020-2025)
  • Table 202. Mexico Microbiome Therapeutics, by Technology USD Million (2020-2025)
  • Table 203. Research Programs/Design for This Report
  • Table 204. Key Data Information from Secondary Sources
  • Table 205. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Microbiome Therapeutics: by Type USD Million (2014-2019)
  • Figure 5. Global Microbiome Therapeutics: by Indication USD Million (2014-2019)
  • Figure 6. Global Microbiome Therapeutics: by Technology USD Million (2014-2019)
  • Figure 7. South America Microbiome Therapeutics Share (%), by Country
  • Figure 8. Asia Pacific Microbiome Therapeutics Share (%), by Country
  • Figure 9. Europe Microbiome Therapeutics Share (%), by Country
  • Figure 10. MEA Microbiome Therapeutics Share (%), by Country
  • Figure 11. North America Microbiome Therapeutics Share (%), by Country
  • Figure 12. Global Microbiome Therapeutics share by Players 2019 (%)
  • Figure 13. Global Microbiome Therapeutics share by Players (Top 3) 2019(%)
  • Figure 14. Global Microbiome Therapeutics share by Players (Top 5) 2019(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Armata Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 17. Armata Pharmaceuticals (United States) Revenue: by Geography 2019
  • Figure 18. Enterome Bioscience (France) Revenue, Net Income and Gross profit
  • Figure 19. Enterome Bioscience (France) Revenue: by Geography 2019
  • Figure 20. Immuron (Australia) Revenue, Net Income and Gross profit
  • Figure 21. Immuron (Australia) Revenue: by Geography 2019
  • Figure 22. OpenBiome (United States) Revenue, Net Income and Gross profit
  • Figure 23. OpenBiome (United States) Revenue: by Geography 2019
  • Figure 24. Osel (United States) Revenue, Net Income and Gross profit
  • Figure 25. Osel (United States) Revenue: by Geography 2019
  • Figure 26. LNC Therapeutics (France) Revenue, Net Income and Gross profit
  • Figure 27. LNC Therapeutics (France) Revenue: by Geography 2019
  • Figure 28. ViThera Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 29. ViThera Pharmaceuticals (United States) Revenue: by Geography 2019
  • Figure 30. Ferring Pharmaceuticals (Switzerland) Revenue, Net Income and Gross profit
  • Figure 31. Ferring Pharmaceuticals (Switzerland) Revenue: by Geography 2019
  • Figure 32. Second Genome (United States) Revenue, Net Income and Gross profit
  • Figure 33. Second Genome (United States) Revenue: by Geography 2019
  • Figure 34. Vedanta Biosciences (United States) Revenue, Net Income and Gross profit
  • Figure 35. Vedanta Biosciences (United States) Revenue: by Geography 2019
  • Figure 36. Global Microbiome Therapeutics: by Type USD Million (2020-2025)
  • Figure 37. Global Microbiome Therapeutics: by Indication USD Million (2020-2025)
  • Figure 38. Global Microbiome Therapeutics: by Technology USD Million (2020-2025)
  • Figure 39. South America Microbiome Therapeutics Share (%), by Country
  • Figure 40. Asia Pacific Microbiome Therapeutics Share (%), by Country
  • Figure 41. Europe Microbiome Therapeutics Share (%), by Country
  • Figure 42. MEA Microbiome Therapeutics Share (%), by Country
  • Figure 43. North America Microbiome Therapeutics Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Armata Pharmaceuticals (United States)
  • Enterome Bioscience (France)
  • Immuron (Australia)
  • OpenBiome (United States)
  • Osel (United States)
  • LNC Therapeutics (France)
  • ViThera Pharmaceuticals (United States)
  • Ferring Pharmaceuticals (Switzerland)
  • Second Genome (United States)
  • Vedanta Biosciences (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation